Introduction
Executive Summary
ALK-positive Non-Small Cell Lung Cancer: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• ALK-positive Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Ensartinib: Betta Pharmaceuticals/Xcovery
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
• Product Description
• Research and Development
• Product Development Activities
Early Stage Products (Phase I)
• Comparative Analysis
PLB1003: Beijing Pearl Biotechnology Limited Liability Company
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
ALK-positive Non-Small Cell Lung Cancer Key Companies
ALK-positive Non-Small Cell Lung Cancer Key Products
ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
ALK-positive Non-Small Cell Lung Cancer Analyst Views
ALK-positive Non-Small Cell Lung Cancer Key Companies
Appendix

List of Tables
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for ALK-positive Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

List of Companies
• GlaxoSmithKline
• Novartis
• AstraZeneca
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck
• Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Ariad Pharmaceutica
• Takeda
• Chia Tai Tianqing Pharmaceutical Group
• Akeso